Clinical Trials Logo

Inflammatory Breast Cancer clinical trials

View clinical trials related to Inflammatory Breast Cancer.

Filter by:

NCT ID: NCT06131632 Not yet recruiting - Clinical trials for Inflammatory Breast Cancer

Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy

ConSIBreC
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Inflammatory breast cancer is an aggressive and rare form of breast cancer, which accounts for 2-3% of all breast cancers. The classic presentation of inflammatory breast cancer includes erythema, edema, and peau d'orange of at least one/third of the breast. Current treatment of inflammatory breast cancer include: neoadjuvant chemiotherapy, modified radical mastectomy and radiation therapy. In the last two decades the development of new targeted therapies has significantly improved the efficacy of neoadjuvant chemiotherapy allowing a de-escalation of surgical treatment in patients with non-inflammatory breast cancer that achieve clinical complete response. There are few retrospective studies that evaluate implications of surgical treatment on survival among these patients. This may justify trial aims to investigate the possible use of the breast conserving surgery in patients with inflammatory breast cancer that achieve clinical complete response after neoadjuvant chemiotherapy.

NCT ID: NCT05415215 Active, not recruiting - Clinical trials for Locally Advanced Breast Cancer

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

ProHer
Start date: July 5, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

NCT ID: NCT05383196 Recruiting - Breast Cancer Clinical Trials

Onvansertib + Paclitaxel In TNBC

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: - Onvansertib - Paclitaxel

NCT ID: NCT04660929 Active, not recruiting - Breast Cancer Clinical Trials

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

NCT ID: NCT04636710 Recruiting - Breast Cancer Clinical Trials

Refining Local-Regional Therapy for IBC

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This Feasibility study is trying to determine: - If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. - The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. - The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer - Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.

NCT ID: NCT04030507 Recruiting - Breast Cancer Clinical Trials

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Start date: July 26, 2019
Phase: N/A
Study type: Interventional

This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

NCT ID: NCT03515798 Recruiting - Clinical trials for Inflammatory Breast Cancer

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

PELICAN
Start date: July 24, 2018
Phase: Phase 2
Study type: Interventional

This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue and blood samples will be collected pre- and post-treatment for translational research.

NCT ID: NCT02879513 Recruiting - Clinical trials for Inflammatory Breast Cancer

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This trial will compare the administration of 2 cycles of paclitaxel and cisplatin (DP) versus 4 cycles of CEF as adjuvant chemotherapy for the patients with locally advanced breast cancer and who were pathological partial response to DP as neoadjuvant chemotherapy. Those who had pathological complete response to DP will be randomized to have 2 cycles of DP or have no further chemotherapy.

NCT ID: NCT02682693 Completed - Clinical trials for Inflammatory Breast Cancer

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

GeparX
Start date: February 13, 2017
Phase: Phase 2
Study type: Interventional

Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models. In a retrospective analysis it could be demonstrated that elevated expression of RANK was found in 14.5% of patients overall, with a significant predominance in patients with hormone-receptor-negative disease. Expression of RANK was associated with a higher pathological complete response rate but with a shorter disease-free and overall survival. The ABCSG-18 study showed that adjuvant denosumab reduces clinical fractures, improves bone health, and can be administered without added toxicity. It appears therefore reasonable to test denosumab, a clinically available antibody against RANKL in patients with hormone-receptor-negative primary breast cancer as an adjunct to neoadjuvant chemotherapy for its ability to increase pCR rate and improve outcome in relation to the expression of RANK.

NCT ID: NCT02623972 Active, not recruiting - Clinical trials for Inflammatory Breast Cancer

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Start date: February 26, 2016
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.